Is there a Role for Targeted Focal Therapy of Prostate Cancer

Loading...

Media is loading
 

Start Date

6-1-2012 1:00 PM

End Date

6-1-2012 2:00 PM

Description

Presentation: 50 minutes

Learning Objectives:

1. To be able to cite the percent of patients who are over treated with local therapy.

2. To describe the technique for mapping biopsies.

3. To develop a follow-up algorithm for men treated with targeted therapy or active surveillance.

Comments

E. David Crawford, M.D., is a professor of surgery, urology, and radiation oncology and head of urologic oncology in the Urologic Oncology Department at the University of Colorado Denver in Aurora, Colorado. He also serves as associate director of the University of Colorado Cancer Center in Denver.

Dr. Crawford earned his medical degree from the University of Cincinnati in Ohio. He completed his residency in the Department of Surgery at Good Samaritan Hospital in Cincinnati, followed by a clinical fellowship in urology at the University of California Medical Center in Los Angeles. He is a fellow of the American College of Surgeons and board certified by the American Board of Urology.

Considered a "legend in urology" by the Canadian Journal of Urology, Dr. Crawford has been the recipient of numerous research grants and has participated in several Southwest Oncology Group and National Cancer Institute protocols. In addition, to his tenure of chair of the genitourinary committee for the Southwest Oncology Group for 28 years and current chair of the National Prostate Cancer Education Council, Dr. Crawford is a member of the Prostate Cancer Trialists Collaborative Group and the Alliance for Prostate Cancer Prevention.

This document is currently not available here.

Share

COinS
 
Jun 1st, 1:00 PM Jun 1st, 2:00 PM

Is there a Role for Targeted Focal Therapy of Prostate Cancer

Presentation: 50 minutes

Learning Objectives:

1. To be able to cite the percent of patients who are over treated with local therapy.

2. To describe the technique for mapping biopsies.

3. To develop a follow-up algorithm for men treated with targeted therapy or active surveillance.